J&J, Legend Shrug Off Carvykti’s Challengers with New Phase III Data
With nearly 90% of patients showing no detectable cancer cells after treatment, J&J and Legend’s Carvykti could stave off competition from emerging CAR T therapies such as Gilead and Arcellx’s anito-cel.
J&J, Legend Shrug Off Carvykti’s Challengers with New Phase III Data Read More »
